Everpar Advisors LLC Has $269,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Everpar Advisors LLC cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 667 shares of the pharmaceutical company’s stock after selling 26 shares during the period. Everpar Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $269,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at $25,000. Highline Wealth Partners LLC acquired a new position in Vertex Pharmaceuticals during the 3rd quarter worth about $27,000. Dunhill Financial LLC grew its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares during the last quarter. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at about $33,000. Finally, Truvestments Capital LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $35,000. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on VRTX shares. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Barclays dropped their target price on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research report on Friday, December 20th. Stifel Nicolaus raised their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $422.00 on Friday. The business has a 50 day simple moving average of $442.83 and a 200 day simple moving average of $466.48. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same period in the previous year, the company posted $3.67 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.